---
schema_version: "secwatch.filing_event.v1"
accession: "0000898432-23-000419"
form_type: "8-K"
ticker: "OSRH"
cik: "0001840425"
company_name: "OSR Holdings, Inc."
filed_at: "2023-06-28T23:59:59+00:00"
generated_at: "2026-06-13T15:43:02.165345+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Bellevue Life Sciences issues $200K sponsor note; Nasdaq audit committee deficiency after director resignation

## Summary
- Issued $200K unsecured promissory note to sponsor; no interest, convertible to units at $10/unit.
- Audit committee now has only two independent directors after director resignation; Nasdaq non-compliance with Rule 5605(c)(2)(A).
- Intends to regain compliance within the cure period under Nasdaq rules.
- Note payable on earlier of Dec 31, 2024 or business combination; repayment from trust only if no deal.

## SEC filing metadata
- accession: 0000898432-23-000419
- form_type: 8-K
- ticker: OSRH
- cik: 0001840425
- company_name: OSR Holdings, Inc.
- filed_at: 2023-06-28T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 1.01, 2.03, 3.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000419/0000898432-23-000419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000419/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000898432-23-000419
- JSON: https://secwatch.observer/filing/0000898432-23-000419.json
- Plain text: https://secwatch.observer/filing/0000898432-23-000419.txt

## Key facts
- Debt Financings
  OSR Holdings, Inc. incurred loan of $200,000 with Bellevue Global Life Sciences Investors LLC maturing earlier of December 31, 2024 or the date on which the Company consummates an initial business combination.
  - Instrument: loan
  - Principal: $200,000
  - Counterparty: Bellevue Global Life Sciences Investors LLC
  - Maturity: earlier of December 31, 2024 or the date on which the Company consummates an initial business combination
  - Event: incurrence
  source text: On June 23, 2023, Bellevue Life Sciences Acquisition Corp., a Delaware corporation and blank check company (the “Company”), issued an unsecured promissory note (the “Note”) in the principal amount of $200,000 to Bellevue Global Life Sciences Investors LLC, the Company’s initial public offering sponsor (the “Sponsor”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000419/0000898432-23-000419-index.htm
- Listing & Compliance Notices
  OSR Holdings, Inc. received a nasdaq deficiency notice notice regarding audit committee (rules 5605(c)(2)(A), 5605(c)(4)(B)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: audit committee
  - Rules: 5605(c)(2)(A), 5605(c)(4)(B)
  source text: June 27, 2023 that the Company is not currently in compliance with Nasdaq Listing Rule 5605(c)(2)(A) (the “Listing Rule”), but that it intends to regain compliance within the cure period provided by section (c)(4)(B) of the Listing Rule. The Listing Rule requires the Audit Committee (the “Audit Committee”) of the Company’s Board of Directors (the “Board”) be composed of at least three members, each of whom must meet independence requirements under the Nasdaq Listing Rules and the Securities Exchange Act of 1934, as amended. Upon the effective date of Mr. Euh’s resignation from the Company’s
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840425/000089843223000419/0000898432-23-000419-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.